SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
Primary Objective
The primary objective of this expanded access program (EAP) is to provide early access to treatment with SNDX-5613 in patients with R/R acute leukemias.
Details
Age
Adult
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Christine McMahon
Study ID
Protocol Number: 23-2063
More information available at ClinicalTrials.gov: NCT05918913
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers